FEB 02, 2020 7:58 AM PST

New T Cell Therapy is a Universal Approach to Target Cancer

WRITTEN BY: Carmen Leitch

The human immune system uses killer T cells to destroy other dangerous cells. For years, researchers have been trying to harness the power of these cells to kill cancer. Current T-cell therapies harvest T cells from cancer patients, modify the cells in the lab to make them more efficient at recognizing and eliminating cancer cells and then return them to the patient. CAR-T cell therapy is now the most common kind of T-cell therapeutic, and while it can be personalized for a patient, it only works against a few types of cancer, and cannot target solid tumors.

Scientists at Cardiff University have now found a type of T cell that carries a unique T cell reporter (TCR) that can identify and kill most kinds of human cancers but leaves healthy cells alone. The TCR can recognize a molecule found on both cancerous cells and healthy cells, but it can tell the difference between normal and cancerous cells; it only attacks cancer. This finding opens the door for immunotherapies that can be widely used to target many kinds of cancer.

T cells find dangerous and anomalous cells by scanning their surfaces, looking for proteins that are attached to molecules called human leukocyte antigen (HLA); these tell the killer T cells more about what is inside of the cells. Different people carry very different HLAs, so T cell therapies must be specialized for the individual. But the newly-identified TCR can find cancers by looking at a molecule called MR1, which is like HLAs.

MR1 is not variable between individuals, however, unlike HLAs, so it could be useful in a broadly applicable T cell therapy. When the TCR is present on T cells, they can find and kill many kinds of cancer including blood, bone, breast, colon, cervical, kidney, ovarian, prostate, and skin cancers and ignore normal cells. The findings were tested in a rodent that modeled human cancer and the human immune system. The test showed that it worked as well as a currently used CAR-T therapy. TCR-modified T cells also destroyed cancer cells from melanoma patients while leaving healthy cells alone.

It's very unusual to identify a TCR that can specifically target many types of cancer, raising the prospect of a universally applicable cancer therapy, noted the lead study author Professor Andrew Sewell, an expert in T-cells at Cardiff University’s School of Medicine.

Professor Sewell at work in the lab. / Credit: Cardiff University

“We hope this new TCR may provide us with a different route to target and destroy a wide range of cancers in all individuals. Current TCR-based therapies can only be used in a minority of patients with a minority of cancers," said Sewell. “Cancer-targeting via MR1-restricted T cells is an exciting new frontier - it raises the prospect of a ‘one-size-fits-all’ cancer treatment; a single type of T cell that could be capable of destroying many different types of cancers across the population. Previously nobody believed this could be possible.”

The researchers are now learning more about the physiological mechanisms that explain how TCR recognizes cancer. It may have to do with metabolic changes in the cell, and how MR1 presents chemicals on the surface of cancer cells. The researchers are hopeful that they will be able to test this strategy in patients soon.

First, safety testing will be critical to ensure that killer T cells that have been modified with this newly-identified TCR are only targeting cancer cells, noted Sewell. “There are plenty of hurdles to overcome however if this testing is successful, then I would hope this new treatment could be in use in patients in a few years’ time,” he added.

“If this transformative new finding holds up, it will lay the foundation for a universal T cell medicine, mitigating against the tremendous costs associated with the identification, generation, and manufacture of personalized T cells," added Professor Awen Gallimore, of the University’s division of infection and immunity and cancer immunology lead for the Wales Cancer Research Centre. “This is truly exciting and potentially a great step forward for the accessibility of cancer immunotherapy.”

Sources: Cardiff University, Nature Immunology

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
DEC 30, 2020
Cell & Molecular Biology
Measuring Electrical Differences Inside of Live Cells
DEC 30, 2020
Measuring Electrical Differences Inside of Live Cells
Electricity is a key aspect of life, and is required for organisms to move and communicate. The movement of tiny charged ...
JAN 05, 2021
Genetics & Genomics
Integrator: A New Type of Transcriptional Control is Discovered
JAN 05, 2021
Integrator: A New Type of Transcriptional Control is Discovered
The study of the genome once seemed like a straightforward process: a specific short sequence of three nucleotide bases ...
JAN 31, 2021
Cell & Molecular Biology
Humans Drank Milk Long Before Their Bodies Could Tolerate It
JAN 31, 2021
Humans Drank Milk Long Before Their Bodies Could Tolerate It
Scientists and archaeologists have long sought to learn when humans started consuming milk. They have tried to use indir ...
FEB 09, 2021
Plants & Animals
Venus Flytraps Generate Magnetic Fields
FEB 09, 2021
Venus Flytraps Generate Magnetic Fields
The Venus flytrap (Dionaea muscipula) might be the most famous carnivorous plant; it can entice prey to land on its leaf ...
FEB 16, 2021
Immunology
Hugs From Immune Cells Heal Muscle
FEB 16, 2021
Hugs From Immune Cells Heal Muscle
Australian researchers have discovered a regenerative factor produced by immune cells that drives the repair and regener ...
FEB 15, 2021
Cell & Molecular Biology
Why SARS-CoV-2 Mutations Make the Virus More Infectious
FEB 15, 2021
Why SARS-CoV-2 Mutations Make the Virus More Infectious
The SARS-CoV-2 pandemic virus that causes COVID-19 has now had ample opportunity to infect millions, which has presented ...
Loading Comments...